ChromaDex has announced the initiation of a clinical study at The University of Mississippi to examine the effects of its pterostilbene ingredient in people with lipid disorders.
The clinical trial is being conducted at the UM Medical Center in Jackson. Participants will receive high and low doses of pterostilbene – a compound found in grapes and blueberries and chemically related to resveratrol - with and without grape extract, or a placebo.
“Pterostilbene has significant promise, and we hope it will offer a useful non-prescription option for metabolic disorders. In addition to cholesterol and blood pressure, we will be evaluating urine tests and monitoring for inflammatory markers,” said Daniel Riche, assistant professor of pharmacy practice and medicine, and the study’s principal investigator.
“The commencement of our pTeroPure pterostilbene clinical study with the University of Mississippi marks another significant milestone for ChromaDex,” said Frank Jaksch, CEO and co-founder of ChromaDex.
“Most people may not yet know of pterostilbene, but we believe this naturally occurring compound’s improved activity and potency may soon make it as well known as its highly-successful, well known relative, resveratrol,” added Jaksch.